查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1615440

神經膠質瘤治療市場：按神經膠質瘤類型、治療類型、最終用戶、分銷管道分類 - 全球預測 2025-2030

Glioma Treatment Market by Type of Glioma (High-grade Gliomas, Low-grade Gliomas), Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), End-user, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

神經膠質瘤治療市場2023年估值為49.5億美元，預計到2024年將達52.9億美元，複合年成長率為7.43%，預計到2030年將達到81.8億美元。

神經膠質瘤治療是指旨在治療神經膠質瘤的綜合方法和治療方法，神經膠質瘤是一種由神經膠質細胞產生的腦腫瘤。這些腫瘤的侵襲性加劇了對神經膠質瘤治療的需求，需要從手術干預和放射線治療到尖端免疫療法和標靶藥物的創新解決方案。應用範圍涵蓋醫院、專業癌症治療中心和個人化居家醫療環境，以滿足不同疾病階段的不同患者的需求。主要的最終用途領域包括專注於開發和提供有效治療方法的醫療保健提供者和製藥公司。市場成長受到多種因素的影響，例如腦腫瘤盛行率的增加、醫療技術的進步以及政府促進癌症研究的措施。此外，正在進行的臨床試驗和早期診斷意識的提高也為創新提供了重要的機會。公司可以透過投資生物標記發現研究和非侵入性治療方法的開發來利用這一潛力。然而，市場擴張面臨治療成本上升、監管複雜性以及新興地區先進治療方法方法有限等挑戰。快速的技術進步正在塑造競爭格​​局，因此企業必須優先考慮研發並建立策略夥伴關係。最有前途的創新領域包括個人化醫療方法、將人工智慧整合到診斷工具中以及擴展遠端醫療用於患者管理。市場動態是動態的，其特徵是市場競爭和治療通訊協定的不斷演變。成功的企業必須專注於擴大產品平臺、加強與研究機構的合作、開拓開拓的市場，以保持成長並在市場中脫穎而出。

主要市場統計
基準年[2023] 49.5億美元
預計年份 [2024] 52.9億美元
預測年份 [2030] 81.8億美元
複合年成長率（%） 7.43%

市場動態：揭示快速發展的神經膠質瘤治療市場的關鍵市場洞察

供需的動態交互作用正在改變神經膠質瘤治療市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球神經膠質瘤盛行率不斷增加
    • 神經膠質瘤治療改革和支持計劃
  • 市場限制因素
    • 聯合治療高成本
  • 市場機會
    • 精準醫療技術的進步
    • 旨在發現神經膠質瘤新治療方法的聯合研究和開發工作
  • 市場挑戰
    • 目前治療方法的功效有限且副作用大

波特五力：駕馭神經膠質瘤治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解神經膠質瘤治療市場的外部影響

外部宏觀環境因素在塑造神經膠質瘤治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解神經膠質瘤治療市場的競爭格局

對神經膠質瘤治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣神經膠質瘤治療市場供應商的績效評估

FPNV定位矩陣是評估神經膠質瘤治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製神經膠質瘤治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，神經膠質瘤治療市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 神經膠質瘤盛行率在全球範圍內不斷增加
      • 改革和支持神經膠質瘤治療的舉措
    • 抑制因素
      • 聯合治療費用高
    • 機會
      • 精準醫療技術的進步
      • 聯合研究和開發旨在發現神經膠質瘤的新治療方法
    • 任務
      • 目前的治療方法效果有限且副作用大
  • 市場區隔分析
    • 治療類型：由於放射線治療越來越受到多種惡性的青睞。
    • 最終用戶：研究機構積極致力於推進神經膠質瘤治療並開發新的治療策略。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按神經膠質瘤類型分類的神經膠質瘤治療市場

  • 高惡性惡性膠質瘤
  • 惡性膠質瘤

第7章依治療類型分類的神經膠質瘤治療市場

  • 化療
  • 免疫療法
  • 放射治療
  • 標靶治療

第8章神經膠質瘤治療市場：依最終用戶分類

  • 醫院
  • 調查機構
  • 專科診所

第9章神經膠質瘤治療市場：按分銷管道

  • 醫院藥房
  • 當地藥房
  • 網路藥房

第10章美洲膠質瘤治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區神經膠質瘤治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的膠質瘤治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • TLX101-CDx PET 顯影劑在神經膠質瘤表徵和治療的進展
    • MimiVax, Inc. 獲得策略性投資以推進 SurVaxM 在造口治療方面的發展
    • Rigel Pharmaceuticals, Inc. 和 CONNECT 合作透過創新臨床試驗推進兒科高級別神經膠質瘤治療
    • Thermo Fisher 和 UCSF 合作生產用於腫瘤和罕見疾病的先進細胞療法
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • Azurity Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Emcure Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche Ltd
  • Intas Pharmaceuticals Ltd.
  • Karyopharm Therapeutics Inc.
  • Mayo Clinic
  • Merck & Co Inc.
  • MimiVax, Inc.
  • Pfizer Inc.
  • Rigel Pharmaceuticals Inc.
  • Sumitomo Dainippon Pharma Oncology Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-CD5A9334CE36

The Glioma Treatment Market was valued at USD 4.95 billion in 2023, expected to reach USD 5.29 billion in 2024, and is projected to grow at a CAGR of 7.43%, to USD 8.18 billion by 2030.

Glioma treatment refers to the comprehensive methodologies and therapies aimed at managing gliomas, a type of brain tumor arising from glial cells. The necessity for glioma treatment is underscored by the aggressive nature of these tumors, necessitating innovative solutions that can range from surgical interventions and radiation therapy to cutting-edge immunotherapies and targeted drugs. The scope of application extends to hospitals, specialized cancer treatment centers, and personalized home care settings, catering to diverse patient needs across different stages of the disease. Key end-use segments include healthcare providers and pharmaceutical companies focusing on the development and delivery of efficacious therapies. Market growth is influenced by several factors, including increasing prevalence of brain tumors, advances in medical technology, and government initiatives promoting cancer research. Moreover, ongoing clinical trials and heightened awareness about early diagnosis present significant opportunities for innovation. Companies can capitalize on these potentials by investing in research for biomarker discovery and development of non-invasive therapeutic options. However, market expansion faces challenges such as high treatment costs, regulatory complexities, and limited availability of advanced therapies in emerging regions. The competitive landscape is shaped by rapid technological advancements, making it imperative for businesses to prioritize R&D and forge strategic partnerships. Areas with the most promise for innovation include personalized medicine approaches, integration of artificial intelligence in diagnostic tools, and expansion of telemedicine for patient management. The glioma treatment market is dynamic, characterized by fierce competition and the constant evolution of therapeutic protocols. Firms looking to thrive should focus on expanding their product pipelines, enhancing collaboration with research bodies, and tapping into underserved markets to sustain growth and achieve significant market differentiation.

KEY MARKET STATISTICS
Base Year [2023] USD 4.95 billion
Estimated Year [2024] USD 5.29 billion
Forecast Year [2030] USD 8.18 billion
CAGR (%) 7.43%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glioma Treatment Market

The Glioma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of gliomas globally
    • Reforms and support initiatives for glioma treatment
  • Market Restraints
    • High cost of combination treatment
  • Market Opportunities
    • Advancements in precision medicine technologies
    • Collaborative R&D efforts aimed at discovering novel therapies for glioma
  • Market Challenges
    • Limited efficacy and side effects of current treatments

Porter's Five Forces: A Strategic Tool for Navigating the Glioma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glioma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glioma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glioma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glioma Treatment Market

A detailed market share analysis in the Glioma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glioma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glioma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glioma Treatment Market

A strategic analysis of the Glioma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glioma Treatment Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Azurity Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd, Intas Pharmaceuticals Ltd., Karyopharm Therapeutics Inc., Mayo Clinic, Merck & Co Inc., MimiVax, Inc., Pfizer Inc., Rigel Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Glioma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type of Glioma, market is studied across High-grade Gliomas and Low-grade Gliomas.
  • Based on Treatment Type, market is studied across Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy.
  • Based on End-user, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Local Pharmacies, and Online Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of gliomas globally
      • 5.1.1.2. Reforms and support initiatives for glioma treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of combination treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in precision medicine technologies
      • 5.1.3.2. Collaborative R&D efforts aimed at discovering novel therapies for glioma
    • 5.1.4. Challenges
      • 5.1.4.1. Limited efficacy and side effects of current treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Growing preference for radiation therapy for widespread and aggressive tumors due to its efficacy
    • 5.2.2. End-user: Research institutes actively working on advancing glioma treatment and developing new therapeutic strategies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Glioma Treatment Market, by Type of Glioma

  • 6.1. Introduction
  • 6.2. High-grade Gliomas
  • 6.3. Low-grade Gliomas

7. Glioma Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Immunotherapy
  • 7.4. Radiation Therapy
  • 7.5. Targeted Therapy

8. Glioma Treatment Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Research Institutes
  • 8.4. Specialty Clinics

9. Glioma Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Local Pharmacies
  • 9.4. Online Pharmacies

10. Americas Glioma Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Glioma Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Glioma Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Advancements in Glioma Characterization and Treatment Through TLX101-CDx PET Imaging Agent
    • 13.3.2. MimiVax, Inc. Secures Strategic Investments to Advance SurVaxM in Glioblastoma Treatment
    • 13.3.3. Rigel Pharmaceuticals, Inc. and CONNECT Join Forces to Advance Pediatric High-Grade Glioma Treatment Through Innovative Clinical Trial
    • 13.3.4. Thermo Fisher and UCSF Collaborate on Advanced Cell Therapies Manufacturing for Oncological and Rare Diseases
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Azurity Pharmaceuticals, Inc.
  • 3. Bristol-Myers Squibb Company
  • 4. Emcure Pharmaceuticals Ltd.
  • 5. F. Hoffmann-La Roche Ltd
  • 6. Intas Pharmaceuticals Ltd.
  • 7. Karyopharm Therapeutics Inc.
  • 8. Mayo Clinic
  • 9. Merck & Co Inc.
  • 10. MimiVax, Inc.
  • 11. Pfizer Inc.
  • 12. Rigel Pharmaceuticals Inc.
  • 13. Sumitomo Dainippon Pharma Oncology Inc.
  • 14. Sun Pharmaceutical Industries Ltd.
  • 15. Teva Pharmaceuticals Industries Ltd.
  • 16. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLIOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLIOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GLIOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GLIOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GLIOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLIOMA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH-GRADE GLIOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW-GRADE GLIOMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOCAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GLIOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY TYPE OF GLIOMA, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GLIOMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. GLIOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GLIOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023